Scandinavian Biopharma strengthens the organization in regulatory affairs through the recruitment of Åsa Dahlbäck as the new VP Regulatory Affairs.
Åsa has more than 30 years of experience in the biotech industry and extensive knowledge of regulatory activities in biopharmaceutical products and biological drug development projects. She previously has had senior positions at, among others, Sobi as Global Regulatory Affairs Manager, Biovitrum and Pharmacia. She has a Master of Science in Chemical Engineering from KTH Royal Institute of Technology.
“It feels great to be involved in the development of the world’s first ETEC vaccine, for high- as well as low- and middle-income countries.”
“This will be very exciting. It feels great to be involved in the development of the world’s first ETEC vaccine, for high- as well as low- and middle-income countries. I am looking forward to applying my knowledge in drug development projects. From the hands-on work of writing paediatric plans, handling IND / CTA submissions and regulatory advice, to strategic interactions with authorities such as the FDA / EMA,” says Åsa Dahlbäck.
“Åsa’s solid industry experience fits Scandinavian Biopharma perfectly. She is a very valuable addition as we continue our growth journey and our goal to register and pre-qualify ETVAX,” says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Photo of Åsa Dahlbäck: Scandinavian Biopharma